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Prognostic and Predictive Markers in
Metastatic Renal Cell Carcinoma
TO THE EDITOR: Significant progress in systemic therapy ofmet-
astatic renal cell carcinoma (mRCC) has been made over the last 5
years, with a plethora of targeted agents currently approved in differ-
ent clinical settings. However, not all mRCC patients respond to
treatment with these drugs and currently there are no validated bio-
markers to predict clinical outcome. We therefore read with interest
Armstrong et al’s1 report of the prognostic and predictive significance
of baseline serum lactate dehydrogenase (LDH) in patients with
intermediate- and-poor risk mRCC treated in a first-line trial of the
mammalian target of rapamycin (mTOR) inhibitor temsirolimus,
interferon-alfa, or both in combination. As expected, in multivariate
analysis, overall survival (OS)was significantly shorter inpatientswith
LDHmore than 1 the upper limit of normal (ULN) comparedwith
patients with LDH 1ULN at baseline. The importance of a high
baseline LDH as a predictor of response to temsirolimus was also
examined: in patients with LDH more than ULN, median OS with
temsirolimus was 6.9 months versus 4.2 months with interferon-alfa
(hazard ratio, 0.56; 95% CI, 0.38 to 0.81; P  .002). There was no
difference in risk of death between temsirolimus and interferon-alfa
treatment in patients with normal LDH. However, patients with an
elevatedLDHin this trialweremore likely tobeofpoor riskbyMotzer
criteria and it is unlikely that interferon-alfa provided any benefit in
this group2 and, given the associated toxicity, it may even have been
detrimental. Survival comparisons between temsirolimus and
interferon-alfa should therefore be viewed with caution.
The prognostic impact of baseline LDH was evaluated in the
RECORD-1(Renal Cell Cancer TreatmentWith Oral RAD001 Given
Daily) trial of themTOR inhibitor everolimus inmRCC refractory to
anti–vascular endothelial growth factor (VEGF) therapy.3 High LDH
was found to be prognostic for OS, but not progression free survival
(PFS) in univariate analysis, but it was not included in the finalmodel
of multivariate analysis because of its nonlinear effect. High pretreat-
mentLDHishowever aprognosticmarker for bothPFS andOS in the
first-line setting during treatment with the VEGF receptor tyrosine
kinase inhibitor sunitinib and interferon-alfa in predominantly good
or intermediate risk (93%)mRCC4 as well as for OS in the sunitinib-
refractory setting during treatment with the VEGF receptor tyrosine
kinase inhibitor axitinib.5 To examine further the relationship be-
tweenprognosis andLDHduringeverolimus therapy,weevaluatedall
patients with mRCC from our institutional database treated with
inhibitoreverolimus(n57)after failureofprioranti-VEGFtherapy.
Themajority of patients (78%)were of good or intermediate risk.We
found a high baseline LDH to be prognostic for OS, similar to Arm-
strong et al’s results1; themedianOSofpatientswith anormal LDHin
our serieswas8.6months comparedwith6.2months for thosewithan
LDH of more than ULN (hazard ratio, 1.71; 95% CI, 0.99 to 2.96;
log-rank P  .05). We could not evaluate the predictive effect of
baseline LDH owing to a lack of a comparator arm; the retrospective
nature and small single-institution sample size are limitations of
this analysis.
Finally, hypertension is commonly associated with anti-VEGF
therapy and appears to be a class effect. The incidence of all-grade
hypertension ranges between 22% and 55% in various studies with
these agents.6-10 Data suggest that hypertension secondary to treat-
ment with sunitinib is associated with improvement in clinical out-
comes (objective response rate, PFS, and OS)11 and similar results
have been observed with other anti-VEGF agents.12,13 mTOR inhibi-
tors may also have antiangiogenic activity,14 and treatment-emergent
hypertension has been observed as a consequence of treatment with
non-VEGF therapy (eg, cytotoxic agents in non–small-lung cancer in
which it has been found to be prognostic but not predictive of differ-
ential outcome).15Therefore, itwouldbe interesting toknowfromthe
data set reported by Armstrong et al1 whether the development of
hypertension correlated with survival on therapy or correlated with
baseline LDH.
In conclusion, the results of the study by Armstrong et al1 are
encouraging and indicate progress toward predicting the clinical out-
come of mRCC patients treated with a targeted agent. However, fur-
ther corroboration of these findings is needed to establish their
relevance for clinical practice.
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